Development of resistance and perspectives for future therapies against hepatitis B infections: Lessons to be learned from HIV

Infection

Volumn 27, Issue SUPPL. 2, 1999, Pages

  Deres, K ^a   Rubsamen Waigmann H ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA POLYMERASE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; CROSS RESISTANCE; ENZYME INHIBITION; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HEPATITIS B; HIV INFECTIONS; HUMANS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 0344131411     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02561672     Document Type: Conference Paper

References (75)

1. Jaeckel, E., Manns, M. P.: Experience with lamivudine against hepatitis B virus, Intervirology 40 (1997) 322-336.
2. Hepatitis overview. Clinica. Doc. No.: C00529354 (1997).
3. Market dynamics: global opportunities in hepatitis to 2010. Datamonitor Americas. New York (1998).
4. Coleman, P. J., McQuillan, G. M., Moyer, L. A., Lumbert, S. B., Margolis, H. S.; Incidence of hepatitis B virus infection in the United States, 1976-1994: estimates from the National Health and Nutrition Examination Surveys. J. Infect. Dis. 178 (1998) 954-959.
5. Yao, G. B.: Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut 38 (Suppl. 2) (1996) S39-S42.
6. Kane, M. A.: The global epidemiology of hepatitis B: Soz. Präventivmed. 43 (Suppl. 1) (1998) S24-S26.
7. de Jongh, F. E., Janssen, H. L., de Man, R. A., Hop, W. C., Sirhalm, S. W., van Blankenstein, M.: Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver (see comments). Gastroenterology 103 (1992) 1630-1635.
8. Decker, R. H.: Diagnosis. In: Zuckerman, A. J., Thomas, H. C. (eds.): Viral hepatitis. Churchill Livingstone, Edinburgh 1993, pp. 165-184.
9. Rehermann, B., Manns, M. P.: Immunologic aspects of acute and chronic hepatitis B and C. Curr. Opin. Gastroenterol. 12 (1996) 554-559.
10. Rehermann, B., Ferrari, C., Pasquinelli, C., Chisari, F. V.: The hepatitis-B virus persists for decades after patients recover from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Medicine 2 (1996) 1104-1108.
11. Koziel, M. J.: The immunopathogenesis of HBV infection. Antiviral Ther. 3 (Suppl. 3) (1998) 13-24.
12. Pharmaprojects, Doc. No.: PH029050 (1999).
13. Trippler, M., zum Buschenfelde, K. H. M., Gerken, G.: HBV viral load within subpopulations of peripheral blood mononuclear cells in HBV infection using limiting dilution PCR. J. Virol. Methods 78 (1999) 129-147.
14. Chisari, F. V., Ferrari, C.: Hepatitis-B virus immunopathogenesis. Annual Review of Immunology 13 (1995) 29-60.
15. Trepo, C., Zoulim, F., Alonso, C., Petit, M. A., Pichoud, C., Vivitski, L.: Diagnostic markers of viral hepatitis-B and hepatitis-C. Gut 34 (1993) S20-S25.
16. Muller, R., Samuel, D., Fassati, L. R., Benhamou, J. P., Bismuth, H., Alexander, G. J. M.: Eurohep consensus report on the management of liver transplantation for hepatitis-B virus infection. J. Hepatol. 21 (1994) 1140-1143.
17. Marques A. R., Straus, S. E.: Advances in the treatment of chronic hepatitis B virus infection. Reviews in Medical Virology 8 (1998) 223-234.
18. Poordad, F. F., Gish, R. G.: Evolving therapies for the treatment of viral hepatitis. Emerging Drugs 4 (1999) 15-35.
19. Hoofnagle, J. H.: Therapy of viral hepatitis. Digestion 59 (1998) 563-578.
20. Prieto, M., Cordoba, J., Rayon, J. M., Garcia-Herola, A., Berenguer, M., Carraseo, D., Olaso, V., Mir, J., Berenguer, J.: Good response to lamivudine therapy in patients with de novo hepatitis B following orthotopic liver transplantation: a pilot study. Hepatology 28 (Suppl.) (1998) 348A.
21. Perillo, R. P.: Treatment of chronic hepatitis B with IFN: experience in western countries. Semin. Liver Dis. 9 (1989) 240-241.
22. Hoofnagle, J. H., Hanson, R. G., Minuk, G. Y., Pappas, S. C., Schafer, D. F., Dusheiko, G. M., Straus, S. E., Popper, H., Jones, E. A.: Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 86 (1984) 150-157.
23. Minul, G. Y., German, G. B., Bernstein, C., Benarroch, A., Gauthier, T., Sekla, L.: A pilot study of steroid withdrawal followed by oral acyclovir in the treatment of chronic type-B hepatitis. Clin. Invest. Med.-Medicine Clinique et Experimentale 15 (1992) 506-512.
24. Macilwain, C.: NIH, FDA seek lessons from hepatitis-B drug trial death. Nature 364 (1993) 275.
25. Marwick, C.: NIH panel report of 'no flaws' in FIAU trial at variance with FDA report, new probe planned (news). JAMA 272 (1994) 9-11.
26. Fried, M. W., Fong, T. L., Swain, M. G., Park, Y., Beames, M. P., Banks S. M., Hoofnagle, J. H., Dibisceglie, A. M.: Therapy of chronic hepatitis-B with a 6-month course of ribavirin. J. Hepatol. 21 (1994) 145-150.
27. Gish, R. G., Lau, J. Y. N., Brooks, L., Fang, J. W. S., Steady, S. L., Imperial, J. C., Garciakennedy, R., Esquivel, C. O., Keeffe, E. B.: Ganciclovir treatment of hepatitis-B virus infection in liver-transplant recipients. Hepatology 23 (1996) 1-7.
28. Anand, B. S., Yoffe, B., Young, J. B.: Ganciclovir treatment of active hepatitis B virus infection in a heart transplant patient. J. Clin. Gastroenterol. 22 (1996) 144-146.
29. Nelson, H.: FDA advised to license three anti-HIV agents (news). Lancet 346 (1995) 1358.
30. Balzarini, J.: Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharmacy World and Science 16 (1994) 113-126.
31. Hong, J. H., Choi, Y., Chun, B. K., Lee, K., Chu, C. K.: Current status of anti-HBV chemotherapy. Archives of Pharmacal Research 21 (1998) 89-105.
32. Severini, A., Liu, X. Y., Wilson, J. S., Tyrrell, D. L.: Mechanism of inhibition of duck hepatitis B virus polymerasc by(-)-beta-L-2′,3′-dideoxy-3′-thiacytidine, Antimicrob. Agents Chemother. 39 (1995) 1430-1435.
33. Cui, L., Schinazi, R. F., Gosselin, G., Imbach, J. L., Chu, C. K., Rando, R. F., Revankar, G. R., Sommadossi, J. P.: Effect of betaenantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. Biochem. Pharmacol. 52 (1996) 1577-1584.
34. Parker, W. B., Cheng, Y. C.: Mitochondrial toxicity of antiviral nucleoside analogues. J. NIH Res. 6 (1994) 57-61.
35. Zoulim, F., Dannaoui, E., Borel, C., Hantz, O., Lin, T. S., Liu, S. H., Trepo, C., Cheng, Y. C.: 2′,3′-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob. Agents Chemother. 40 (1996) 448-453.
36. Lai, C. L., Chien, R. N., Leung, N. W. Y., Chang, T. T., Guan, R., Tai, D. I., Ng, K. Y., Wu, P. C., Dent, J. C., Barber, J., Stephenson, S. L., Gray, D. F.: A one-year trial of lumivudine for chronic hepatitis B. N. Engl. J. Med. 330 (1998) 61-68.
37. Dienstag, J. L., Perrillo, R. P., Schiff, E. R., Bartholomew, M., Vicary, C., Rubin, M.: A preliminary trial of lumivudine for chronic hepatitis B infection. N. Engl. J. Med. 333 (1995) 1657-1661.
38. Scrip. Doc. No.: S00622582 (1999).
39. Dienstag, J., Schiff, E. R., Wright, T., Perrillo, R., Hann, H. W., Crowther, L., Woessner, M., Rubin, M., Brown, N., Group US Lamivudine Investigator: Lamivudine treatment for one year in previously untreated US hepatitis B patients: histologie improvement and hepatitis B c antigen scroconversion. Gastroenterology 114 (1998) pA1235.
40. Main, J., Brown, J. L., Howells, C., Galassini, R., Crossey, M., Karayiannis, P., Georgiou, P., Atkinson, G., Thomas, H. C.: A double blind, placebo controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Virol. Hepatitis 3 (1996) 211-215.
41. Scrip, Doc. No.: S00620466, (1999).
42. Scrip, Doc. No.: S006111502, (1999).
43. Gilson, R. J. C., Murray-Lyon, I. M., Nelson, M. R., Rice, S. J., Tedder, R. S., Murray, A., Jaffa, H. S., Weller, I. V. D.: Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection. Hepatology 28 (1998) 1316.
44. Xiong, X., Flores, C., Yang, H., Westland, C. E.,Toole, J. J., Gibbs, C. S.: Mutations in human hepatitis B virus polymerase associated with resistance to lamivudine and famciclovir do not decrease sensitivity to adefovir. Antiviral Res. 37 (1998) pA66.
45. Gibbs, C., Flores, C., Yang, H., Westland, C., Toole, J., Xiong, X.: HBV polymerase mutations associated with resistance to lamivudine and famciclovir do not decrease sensitivity to adefovir. J. Hepatol. 28 (Suppl. 1 ) (1998) 111.
46. Xiong, X. F., Flores, C., Yang, H., Toole, J. J., Gibbs, C. S.: Mutations in hepatitis B DNA polymerase associated resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28 (1998) 1669-1673.
47. Fu, L., Liu, S. H., Cheng, Y. C.: Sensitivity of L-(-)2′,3′-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem. Pharmacol. 57 (1999) 1351-1359.
48. Bain, V. G., Kneteman, N. M., Ma, M. M., Gutfreund, K., Shapiro, J. A., Fischer, K., Tipples, G., Lee, H., Jewell, L. D., Tyrrell, D. L.: Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation.Transplantation 62 (1996) 1456-1462.
49. Tipples, G. A., Ma, M. M., Fischer, K. P., Bain, V. G., Knetemann, N. M., Tyrrell, D. L. J.: Mutation in HBV RNA-dependent DNA-polymerase confers resistance to lamivudine in vivo. Hepatology 24 (1996) 714-717.
50. Ling, R., Mutimer, D., Ahmed, N., Boxall, E. H., Elias, E., Dusheiko, G. M., Harrison,T. J.: Selection of mutations in the hepatitis-B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24 (1996) 711-713.
51. Chayama, K., Suzuki, Y., Kobayashi, M., Kobayashi, M., Tsubota, A., Hashimoto, M., Miyano, Y., koike, H., Kobayashi, M., Koida, I., Arase, Y., Saitoh, S., Murashima, N., Ikeda, K., Kumada, H.: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27 (1998) 1711-1716.
52. Niesters, H. G. M., Honkoop, P., Haagsma, E, B., deMan, R. A., Schalm, S. W., Osterhaus, A. D. M. E.: Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J. Infect. Dis. 177 (1998) 1382-1385.
53. Cane, P. A., Mutimer, D., Ratcliffe, D., Cook, P., Beards, G., Elias, E., Pillay, D.: Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antiviral Ther. 4 (1999) 7-14.
54. Allen, M. I., Deslauriers, M., Andrews, C. W., Tipples, G. A., Walters, K. A., Tyrrell, D. L. J., Brown, N., Condreay, L. D.: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27 (1998) 1670-1677.
55. Yushida, E. M., Ma, M. M., Davis, J. E., Fischer, K. P., Kneteman, N. M., Krb, S. R., Tyrrell, D. L., Bain, V. G.: Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long term follow-up. Can. J. Gastroenterol. 12 (1998) 125-129.
56. De Man, R. A., Bartholomeusz, A., Locarnini, S., Niesters, H. G. M., Zondervan, P. F..: The occurrence of sequential viral mutations in a liver transplant recipient reinfected with hepatitis B: primary famciclovir resistance followed by a lethal hepatitis during acquired lamivudine resistance. J. Hepatol. 26 (Suppl. 1) (1997) 77.
57. deMan, R. A., Bartholomeusz, A. I., Niesters, H. G. M., Zondervan, P. E., Locarnini, S. A.: The sequential occurcnce of viral mutations in liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J. Hepatol. 29 (1998) 669-675.
58. Bartholomeusz, A., Locarnini, S.: Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. International Antiviral News 5 (1997) 123-124.
59. Whalley, S., Manolakopoulos S., Brown, D., Davies, S., Ling, R., Harrison, T., Dusheiko, G.: Emergence of lamivudine resistant HBV is not always associated with HBeAg positive status or a high pre-treatment viral load in patients with chronic infection. Gut 42 (Suppl. 1) (1998) 14.
60. Mutimer, D., Pillay, D., Dragon, E., Tang, H., Ahmed, M., O'Donnell, K., Shaw, J., Burroughs, R., Rand, D., Cane, P., Martin, B., Buchan, S., Boxall, E., Barmat, S., Gutekunst, K., McMaster, P., Elias, E.: High pro-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J. Hepatol. 30 (1999) 715-721.
61. Ling, R., Harrison, T. J.: Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J. Gen. Virol. 80 (Part 3) (1999) 601-606.
62. Ono-Nita, S. K., Kato, N., Shiratori, Y., Masaki, T., Lan, K. H., Carrilho, F. J., Omata, M.: YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 29 (1999) 939-945.
63. Fu, L., Cheng, Y. C.: Role of additional mutations outside the YMDD motif of hepatitis B virus polymcrase in L(-)SddC (3TC) resistance. Biochem. Pharmacol. 55 (1998) 1567-1572.
64. Ladner, S. K., Miller, T. J., King, R. W.: The M539V polymerase variant in human hepatitis B virus demonstrates resistance 10 2′-deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob. Agents Chemother. 42 (1998) 2128-2131.
65. Ladner, S. K., Miller, T. J., Otto, M. J., King, R. W.: The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antiviral Chemistry & Chemotherapy 9 (1998) 65-72.
66. Heathote, J., Schalm, S. W., Cianciara, J., Farrell, G., Feinmann, V., Shermann, M., Dhillon, A. P., Mourat, A. E., Gray, D. F: Lamivudine and intron: a combination treatment in patients with chronic hepatitis B infection. J. Hepatol. 28 (Suppl. 1) (1998) 43.
67. Kim, J. W., Lee, M. Y., Chin, Y. J., Lim, C. Y., Songs, I. H.: Interferon alpha versus interferon alpha and lamivudine in the treatment of chronic active hepatitis B. 8th International Symposium on Viral Hepatitis 121, 22 January 1998.
68. Schiff, E., Karayalcin, S., Grimm, I., Perrillo, R., Dienstag, J., Husa, P., Schalm, S., Crowther, L., Sullivan, M., Woessner, M., McPhillips, P., Brown, N., Group International Lamivudine Investigator: A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 28 (Suppl.) (1998) p388A.
69. Mutimer, D., Naoumov, N., Honkoop, P., Marinos, G., Ahmed, M., deMan, R., McPhillips, P., Johnson, M., Williams, R., Elias, E., Schalm, S.: Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J. Hepatol. 28 (1998) 923-929.
70. Rübsamen-Waigmann, H.: Antiviral therapies: progress, resistance and trends. Nova Acta Leopoldina NF 78 (1999) 295-312.
71. Benson, E. M., Clarkson, J., Law, M., Marshall, P., Kelleher, A. D., Smith, D. E., Patou, G., Stewart, G. J., Cooper, D. A., Ffrench, R. A.: Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. AIDS Res. Hum. Retroviruses 15 (1999) 105-113.
72. Vitiello, A., Ishioka, G., Grey, H. M., Rose, R., Farness, P., Lafond, R., Yuan, L. L., Chisari, F. V., Furze, J., Bartholomeuz, R., Chesnut, R. W.: Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. 1. Induction of a primary cytotoxic T-lymphocyte response in humans. J. Clin. Invest. 95 (1995) 341-349.
73. Pharmaprojects, Doc. No.: PH017693 (1999).
74. Alexopoulou, A., Zafiropoulou, R., Papakonstantinou, A., Hadziyannis, S. J.: Randomised trial in HBeAg negative patients with replicating virus with ganciclovir vs lamivudine in combination with Interferon. Evaluation of long-term efficacy. Hepatology 28 (Suppl.) (1998) 490.
75. Terrault, N. A., Wright, T. L., Roberts, J. P., Ascher, N. L.: Combined short-term hepatitis B immunoglobulin (HBIG) and long-term lamivudine versus HBIG monotherapy as hepatitis B virus prophylaxis in liver transplant recipients. Hepatology 28 (Suppl.) (1998) 389.